retatrutide fda approval status october 2025 Status: July 2026 Update Safety concerns over doctors prescribing
Description
[16] on tirzepatide and Nagendra et al
While GLP-1 degradation is unaffected by kidney function, the clearance of both GLP-1, and to a greater extent its inactive metabolites, is delayed in patients with renal insufficiency [184]
69.American Health Drug Benefits [Internet]
Mol Metab 20:5162
